Emergent BioSolutions Inc/ US29089Q1058 /
| 2024-05-14 9:59:55 PM | Chg. -0.29 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 5.09USD | -5.31% | 27,460 Turnover: 144,149.89 |
-Bid Size: - | -Ask Size: - | 266.2 mill.USD | - | - |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 542.3000 | 644.1000 | 800.1000 | 817.6000 | 382.8000 | ||||||
| Intangible Assets | 712.9000 | 663.1000 | 604.6000 | 728.8000 | 566.6000 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | 1,641.1000 | 1,687.3000 | 1,686.9000 | - | 1,143.7000 | ||||||
| Inventories | 222.5000 | 307 | 350.8000 | 350.7000 | 328.9000 | ||||||
| Accounts Receivable | 270.7000 | 230.9000 | 274.7000 | 159.2000 | 191 | ||||||
| Cash and Cash Equivalents | 167.8000 | 621.3000 | 576.1000 | 642.6000 | 111.7000 | ||||||
| Current Assets | 686.2000 | 1,195.9000 | 1,272.1000 | 1,210.4000 | 679.5000 | ||||||
| Total Assets | 2,327.3000 | 2,883.2000 | 2,959 | 3,166.3000 | 1,823.2000 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 94.8000 | 136.1000 | 128.9000 | 103.5000 | 112.2000 | ||||||
| Long-term debt | 798.4000 | 841 | 809.4000 | 448.5000 | 446.5000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | 63.9000 | 53.2000 | - | - | - | ||||||
| Liabilities | 1,238.8000 | 1,436.2000 | 1,340 | 1,778.6000 | 1,173.9000 | ||||||
| Share Capital | - | - | - | - | - | ||||||
| Total Equity | 1,088.5000 | 1,447 | 1,619 | 1,387.7000 | 649.3000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,327.3000 | 2,883.2000 | 2,959 | 3,166.3000 | 1,823.2000 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,106 | 1,555.4000 | 1,792.7000 | 1,117.5000 | 1,049.3000 | ||||||
| Depreciation (total) | 58.7000 | 59.8000 | 58.5000 | 59.9000 | 65.6000 | ||||||
| Operating Result | 114.1000 | 433.8000 | 352.6000 | -170 | -726.4000 | ||||||
| Interest Income | -38.4000 | -31.3000 | -34.5000 | -37.3000 | -87.9000 | ||||||
| Income Before Taxes | 77.4000 | 407.2000 | 314.4000 | -219 | -731.2000 | ||||||
| Income Taxes | 22.9000 | 102.1000 | 83.5000 | -7.4000 | 29.3000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 54.5000 | 305.1000 | 230.9000 | -211.6000 | -760.5000 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 188 | 536 | 321.1000 | -34.1000 | -206.3000 | ||||||
| Cash Flow from Investing Activities | -96.9000 | -151 | -225 | -381.3000 | 212.3000 | ||||||
| Cash Flow from Financing | -35.9000 | 69.5000 | -141 | 481.2000 | -535.7000 | ||||||
| Decrease / Increase in Cash | 55.6000 | 453.5000 | -45.2000 | 66.3000 | -530.9000 | ||||||
| Employees | 1,834 | 2,200 | - | - | - | ||||||
